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Mihir Raval,1 Alison Gulbis,2 Catherine Bollard,3 Ann Leen,3 Roy Chemaly,4 Elizabeth Shpall,5
Amit Lahoti,6 Partow Kebriaei5BK virus nephropathy is a common cause of graft loss in kidney transplant recipients. Cases of BK nephrop-
athy following allogeneic hematopoietic cell transplantation (HCT) are underreported. An increased inci-
dence of BK virus-associated nephropathy is being seen in the setting of more profound and prolonged
immunosuppression following solid organ transplantation and HCT. We will review diagnostic and treat-
ment modalities for BK-associated nephropathy following allogeneic HCT.
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The BK virus is a member of the Polyomavirus
family and, although ubiquitous in the general popula-
tion, is not pathologic in immunocompetent adults.
The BK virus seroprevalence is 90% in adults [1],
with the virus in latent dormant stage embedded in
the urothelium. Intermittent reactivation with low
level viruria (\106 virus copies/mL of urine) may be
noted in approximately 5% of immunocompromised
patients without consequence [2,3]. However, higher
levels of BK shedding in the urine (.107 virus copies/
mL of urine) has been noted in 20% to 60% of
patients after solid organ transplantation, and is
associated with the risk of developing hemorrhagic
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6/j.bbmt.2011.07.010including ureteral obstruction, hydronephrosis, and
renal allograft loss [2,4-7]. The most reported cases
of BK virus nephropathy or hemorrhagic cystitis
occur after solid organ transplantation secondary to
immunosuppression, but have also been reported in
recipients of allogeneic hematopoietic cell transplants
(HCT) [8-14]. BK viruria has been reported in 50%
of patients after HCT, within 2 month of trans-
plantation [8,9,15,16]. Hemorrhagic cystitis is
commonly associated with BK infection, occurring in
10% to 25% of recipients [8,15], although a direct
correlation for BK viruria and hemorrhagic cystitis
has not been established. In fact, in a multivariate
analysis for predictors of hemorrhagic cystitis in
patients receiving HCT at M. D. Anderson, the
presence of BK viruria was not found to be a
significant factor [17].
Pathogenesis of BK-Associated Nephropathy
Development of BK viruria and associated nephrop-
athies, including hemorrhagic cystitis, is dependent on
several factors including type of conditioning regimen,
use of T cell-depleted grafts, and use of related or
unrelated donor grafts [17,18]. Leung et al. suggested
3 phases for the development of BK virus hemorrhagic
cystitis [19]. First, the conditioning regimen damages
the bladdermucosa, providing a hospitable environment
for theBKvirus to replicate. Second, viral replication be-
comes unchecked in the absence of functional immunity.
Third, there is further damage to the bladder mucosa
with immune reconstitution and the return of anti-BK
virus immunity [19]. Review of the literature suggests
a higher incidence of BK hemorrhagic cystitis with the
use of T cell-depleted grafts [20]. The introduction of1589
Figure 1. Immunohistochemistry images of renal biopsy. SV-40T stain was positive, suggesting BK virus involvement of the tubulointerstitium (A).
Nuclear enlargement and smudge chromatin suggest viral inclusion (B). The presence of tubular casts for IgA is a nonspecific finding associated with
tubulitis and interstitial lymphoplasmacytic infiltrates (C).
Figure 2. Serum creatinine measurements beginning 100 days follow-
ing transplantation in patient diagnosedwith BK-associated hemorrhagic
cystitis and nephropathy following a double cord blood transplant. The
patient developed BK viruria, with .5  108 virus copies/mL urine, as-
sociated with hemorrhagic cystitis, 39 days post-HCT. At 105 days post-
HCT, there was a rise in creatinine up to 3.6 mg/dL that was noted to be
because of bilateral hydronephrosis, diagnosed by renal ultrasound, in
the setting of persistent BK viruria, with improvement in creatinine fol-
lowing placement of bilateral percutaneous nephropathy tubes. Immu-
nosuppression was also discontinued at this time. The presence of
renal failure prohibited the use of cidofovir, so leflunomide was initiated
on day1263, and over the course of 3 weeks, the creatinine decreased
from 6.7mg/dL to 3.5mg/dL, with a 75% reduction in BK viruria from.5
 108 to 1.25  108 copies of virus/mL urine. At approximately 1 year
posttransplantation, 6.86  105 copies of virus/mL of urine was noted
after taking leflunomide for approximately 15 weeks. However, the pa-
tient subsequently developed another rise in her creatinine concurrent
with the development of a pseudomonas urinary tract infection. The pa-
tient remains on leflunomide at 20 mg daily, with no liver or bone mar-
row toxicities noted.
1590 Biol Blood Marrow Transplant 17:1589-1593, 2011M. Raval et al.more powerful immunosuppressive agents, such as
mycophenolate mofetil and tacrolimus, have also likely
increased the reported incidence of BK virus-induced
nephropathy and hemorrhagic cystitis [21].
Diagnosis of BK-Associated Nephropathy
The current diagnostic modalities most commonly
used include screening for the BK viral load in the
urine and serum, and microscopic examination of the
urine to check for Polyomavirus sediments in patients
presenting with hematuria and abnormal renal func-
tion. In 1 report, the group of patients who developed
hemorrhagic cystitis showed evidence for BK viruria at
a median of 23 days followingHCT, with hemorrhagic
cystitis subsequently developing on average 44 days
following HCT [21]. A recent report suggested the
importance of BK viremia as a prognostic marker for
BK nephropathy in children undergoing HCT [22].
Patients with a high BK viral load in the serum
(.10,000 copies/mL) had more severe BK-associated
nephropathy requiring more aggressive treatment, in-
cluding dialysis, with survival approximately 48% at
1 year. In contrast, the group of patients with low se-
rumBK titers (\10,000 copies/mL) had less aggressive
disease with an estimated survival of 89% at 1 year [22].
Thedefinitivediagnosis forBKnephropathy isarenal
biopsy with immunohistochemistry showing presence of
the virus in the renal cells. When, and if, this test is per-
formed depends on the severity of presentation and
whether a definitive diagnosis will change the treatment
plan. Figure 1 illustrates the positive SV-40T stain noted
in the tubulointerstitium of the kidney, nuclear enlarge-
ment, and smudgechromatin, suggestingviral inclusions,
aswell as thepresenceof IgA tubular casts associatedwith
viral infection, which were noted in 1 of our patients who
developed BK-associated nephropathy 214 days follow-
ingadouble cordblood transplant for relapsedacute lym-
phoblastic leukemia (ALL).This patient’s clinical course,
illustrated inFigure2, anddescribed in the followingpar-
agraphs, is representative of the challenges of treatment
for BK-associated nephropathy.
Treatment of BK-Associated Nephropathy
The heterogeneous and complex clinical situations
of patients who develop BK viruria and nephropathy,as well as the lack of large clinical studies, make it chal-
lenging to develop standard guidelines for the treat-
ment of BK virus-associated hemorrhagic cystitis and
nephropathy. Studies suggest that BK virus nephropa-
thy is caused by an imbalance between BK virus repli-
cation and BK virus cellular mediated immunity
[23,24], although the degree of cellular immunity
necessary to prevent reactivation of BK virus after
HCT is not known. Thus, the standard treatment for
BK nephropathy is to first reduce immunosuppre-
ssion with the aim of improving the T cell-mediated
immunity against the virus [23,25], followed by the
Biol Blood Marrow Transplant 17:1589-1593, 2011 1591Evaluation and Management of BK Virus-Associated Nephropathyuse of antiviral agents. Figure 3 shows enzyme-linked
immunosorbent spot (ELISPOT) responses to several
common viruses peritransplantation, including BK vi-
rus, in our patient who developed BK nephropathy. In
this patient, varying levels of immunity against BK vi-
rus was present before the cord blood transplant, but
became absent at 100 days following transplantation
with transient recovery of immunity at 180 days. De-
spite discontinuation of all immunosuppression at
210 days posttransplantation, BK-virus reactive T cells
remained undetectable at 360 days posttransplantation
(Figure 3).Figure 3. Summary of ELISPOTresponses as measured by SFC/105 peripher
VP1. Pretransplantation, the patient was noted to have 10 SFC/2 105 PBMC a
BK-virus reactive T cells remain undetectable at 360 days posttransplantation.
quency of virus-specific IFN-g-secreting T cells.38 Briefly, PBMCs were isolated
specific activity of responder cells after direct stimulation with pepmixes spanni
MP1 and NP1 (Influenza), N and F (RSV), and EBNA1, EBNA3a, EBNA3b, EBNA
peptide libraries (15mers overlapping by 11 amino acids) were purchased from
triplicate. After 20 hours of incubation, plates were developed as previously de
to Zellet Consulting (New York, New York) for quantification. The frequency o
cell numbers.A variety of antiviral agents have been tried, includ-
ing cidofovir and leflunomide, but the duration of
treatment is not standardized [26-30]. Cidofovir ([S]-
1-[3-hydroxy-2-(phosphonomethoxy) propyl] cytosine
[HPMPC]) is an acyclic phosphonate analogue of
dCMP, which has shown antiviral activity against sev-
eral DNA viruses, including BK virus, although its
mechanism of action is still under investigation. New
classes of nucleoside phosphonate derivatives are under
investigation [31]. Leflunomide is an immunomodula-
tory agent that inhibits pyrimidine synthesis and results
in antiproliferative and anti inflammatory effects.al blood mononuclear cells (PBMC) against the BK virus antigens LTand
gainst the VP1 antigen and 40 SFC/2 105 PBMC against the LTantigen.
The previously described ELISPOTassay was used to determine the fre-
by ficoll gradient and plated at 2 105 cells/well. We measured the viral-
ng Hexon and Penton (Adv), IE1 and pp65 (CMV), VP1 and Large T (BK),
3c, LMP1, LMP2, and BZLF1 (EBV). All pepmixes, which are overlapping
JPT Technologies (Berlin, Germany). Each culture condition was run in
scribed [38], dried overnight at room temperature in the dark, then sent
f T cells specific to each antigen was expressed as specific SFC per input
1592 Biol Blood Marrow Transplant 17:1589-1593, 2011M. Raval et al.Leflunomide is converted to its active metabolite, A77
1726 (M1), which inhibits BK virusDNA replication in
the renal tubular epithelium. Thus, the assembly and
release of the virus is inhibited [32-34]. Leflunomide
has been extensively studied in the setting of BK virus
nephropathy developing after renal allografts, but has
not been well studied in HCT. The recommended
starting dose for leflunomide is 20 mg daily, with the
effective drug level of leflunomide to achieve 50%
and 90% reduction in BK virus replication reported
to be 15 to 30 mg/mL and 35 to 100 mg/mL in the
blood, respectively [29]. Associated toxicities include
myelosuppression and liver toxicity [29,33]. The
duration of therapy is not clear, but treatment is
usually continued until there is resolution of viruria.
Because of ongoing kidney failure and the difficulty
of using cidofivir in this setting, we treated our
patient with leflunomide, with a reduction noted in
BK viruria but persistent kidney dysfunction as
manifested by a persistently elevated creatinine
(Figure 2). In a comparison study of cidofovir against
leflunomide for the treatment of BK nephropathy in
solid organ transplants, both drugs had similar rates
of clearing BK viremia, but there was less graft loss
seen with the use of leflunomide [35]. Of interest, in 1
study evaluating the inhibitory effects of cidofivir
against leflunomide against BK virus replication
in vitro, cidofivir was noted to be superior [31].
In addition to antiviral therapies, intravenous
immunoglobulin and fluoroquinolones [36] have
been evaluated for treatment, and were noted to be
inferior to cidofivir and leflunomide [35,37]. Finally,
in addition to drug therapy, the use of cellular-
mediated therapies hold great promise in this setting,
because the pathogenesis of BK-associated complica-
tions is based on poor cellular immunity against the
virus. Based on promising work infusing cytotoxic
T lymphocytes (CTLs) with tri-viral specificity for
Epstein-Barr virus (EBV), cytomegalovirus (CMV),
and adenovirus (ADV) into patients with these persis-
tent viral infections despite traditional drug therapy,
Gerdemann and colleagues [38] are currently develop-
ing an approach to develop multivirus-reactive CTLs
with broader antiviral activity, including activity
against the BK virus.SUMMARY
In conclusion, BK nephropathy developing after
HCT is a pathologic entity that occurs in the setting
of profound immunosuppression. The complexity of
patients makes it difficult to currently standardize
treatment recommendations. Aggressive diagnosis of
patients at higher risk of developing BK-associated
nephropathy (known preexisting kidney disease, per-
sistent BK viruria, persistent hemorrhagic cystitis)with renal biopsy, followed by aggressive immunosup-
presion withdrawal as feasible and earlier treatment
initiation, may help in preventing kidney failure. The
most effective intervention is the reduction in immu-
nosuppression. The addition of antiviral agents such
as cidofovir or leflunomide in the setting of persistent
BK viremia/viruria is helpful. New nucleoside phos-
phonate analogues, currently in development, should
be widely studied in the setting of HCT to provide
more antiviral agent choices for treatment. The choice
of antiviral agent at this time is limited but should be
based on patient tolerability and side effect profile.
Finally, the development of cellular-mediated thera-
pies holds great promise.ACKNOWLEDGMENTS
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